A new insofar as chronobiologic therapeutic approach by atrial natriuretic peptide (ANP) for hypertension and/or congestive heart failure (CHF) is based on the release of ANP from ANP cDNA transfected Chinese Hamster Ovary (CHO) cells encapsulated in polycaprolactone (PCL) tubes. ANP secretion was maintained for at least 6 months. The encapsulated cells remained viable during culturing. Control cells without transferred ANP cDNA were negative. ANP secretion is circadian periodic, peaking around 04:18, shifted to around 07:56 by melatonin treatment. The encapsulation technique, based on principles of chronotherapy, may provide a more efficient gene therapy, applicable for eventual human implantation of gene transferred cells.
Bibliographical noteFunding Information:
National Nature Science Foundation of China (project 39970275, 30070278 for W.Z. and 30070198 for W.C.); U.S. Public Health Service (GM-13981) (F.H.); Dr. h.c. Dr. h.c. Earl Bakken Fund (G.C., F.H.); University of Minnesota Supercomputing Institute (G.C., F.H.).
- CHO cells
- Chinese hamster ovary
- Circadian rhythm
- Congestive heart failure
- atrial natriuretic peptide
- congestive heart failure
- human atrial natriuretic peptide